Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
Rhea-AI Summary
Company (NYSE:DBVT) reports the total number of shares and voting rights as of November 30, 2025 under Article 223-16 of the AMF General Regulations.
As of 11/30/2025 the total number of shares is 200,777,718. The total gross voting rights equals 200,777,718 and the total net voting rights is 200,667,869 (net total excludes shares without voting rights). ISIN: FR0010417345.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, DBVT declined 0.62%, reflecting a mild negative market reaction. This price movement removed approximately $3M from the company's valuation, bringing the market cap to $467M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers showed mixed moves: CADL up 13.11%, ANNX up 2.65%, NGNE up 1.77%, while OMER and CAPR fell 4.51% and 3%, suggesting stock-specific factors for DBVT.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 02 | Capital structure update | Neutral | -0.6% | Reported total shares and gross/net voting rights as of Nov 30, 2025. |
| Nov 11 | Clinical trial update | Positive | -1.8% | Completed last patient visit in VITESSE Phase 3 VIASKIN Peanut trial. |
| Nov 04 | Conference participation | Neutral | +0.8% | Announced CEO fireside chat at Guggenheim healthcare innovation conference. |
| Nov 03 | Management change | Positive | -2.7% | Appointed Kevin Trapp as Chief Commercial Officer for Viaskin Peanut strategy. |
| Nov 03 | Capital structure update | Neutral | -2.7% | Disclosed total shares and voting rights as of October 31, 2025. |
Positive corporate and clinical updates have previously seen negative next-day reactions, while routine voting-rights disclosures have had modest price impact.
Over the last few months, DBV Technologies reported multiple routine share and voting-right updates and key clinical and leadership milestones. VITESSE Phase 3 completed last patient visit in a 654-subject study across 86 sites, with topline data targeted for Q4 2025. The company appointed a Chief Commercial Officer to prepare for potential Viaskin Peanut launches and regularly reports its total shares and voting rights, such as the 200,777,718 shares and associated voting rights as of November 30, 2025.
Market Pulse Summary
This announcement formalizes DBV Technologies’ capital structure as of November 30, 2025, reporting 200,777,718 shares and matching gross voting rights, with net voting rights slightly lower after excluding non-voting shares. It follows similar monthly disclosures and sits against a backdrop of ongoing Phase 3 development for Viaskin Peanut and prior financing activities. Investors may watch future updates on clinical milestones, liquidity, and any further changes in share count or voting structure.
Key Terms
isin financial
AI-generated analysis. Not financial advice.
Information Regarding the Total Number of Voting Rights and
Total Number of Shares of the Company as of November 30, 2025
(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)
Market : NYSE Euronext Paris
ISIN Code: FR 0010417345
| Date | Total number of shares | Total number of voting rights |
| 11/30/2025 | 200,777,718 | Total gross of voting rights: 200,777,718 |
| Total net* of voting rights: 200,667,869 |
* Net total = total number of voting rights attached to shares – shares without voting rights
Attachment
FAQ
What is the total number of shares for DBVT as of November 30, 2025?
How many total voting rights does DBVT have on November 30, 2025?
What is the difference between gross and net voting rights for DBVT on 11/30/2025?
What ISIN is associated with DBVT's November 30, 2025 voting rights disclosure?
Why does DBVT publish the total number of voting rights on November 30, 2025?
